OTCMKTS:ACUR Acura Pharmaceuticals (ACUR) Stock Price, News & Analysis $0.0035 +0.00 (+9.38%) (As of 12/20/2024 05:55 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest About Acura Pharmaceuticals Stock (OTCMKTS:ACUR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Acura Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0035▼$0.003550-Day Range N/A52-Week Range$0.00▼$0.75Volume1,000 shsAverage Volume3,161 shsMarket Capitalization$232,221.50P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAcura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc. and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was formerly known as Halsey Drug Co., Inc. The company was incorporated in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals, Inc. operates as a subsidiary of Abuse Deterrent Pharma, LLC.Read More… Receive ACUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acura Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACUR Stock News HeadlinesUS launches investigation into 1.4 million Honda vehiclesNovember 13, 2024 | msn.comAcura Pharmaceuticals secures additional financing amid challengesOctober 4, 2024 | uk.investing.comWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.December 22, 2024 | Behind the Markets (Ad)1 dead, 2 others injured after high-speed chase leads to crash in Cumberland County, NC troopers sayAugust 19, 2024 | msn.comNew Omaha casino reopens after cooling system is restoredAugust 16, 2024 | yahoo.comPlumes of smoke rise from town in southern Lebanon as tensions escalate between Hezbollah and IsraelAugust 16, 2024 | yahoo.comWho are Lincoln Park Young Professionals at center of bid rigging scandal?August 15, 2024 | yahoo.com3.9-magnitude earthquake hits near Lake ElsinoreAugust 15, 2024 | yahoo.comSee More Headlines ACUR Stock Analysis - Frequently Asked Questions How have ACUR shares performed this year? Acura Pharmaceuticals' stock was trading at $0.0001 at the beginning of 2024. Since then, ACUR shares have increased by 3,400.0% and is now trading at $0.0035. View the best growth stocks for 2024 here. How were Acura Pharmaceuticals' earnings last quarter? Acura Pharmaceuticals, Inc. (OTCMKTS:ACUR) announced its earnings results on Friday, February, 28th. The specialty pharmaceutical company reported $0.00 earnings per share for the quarter. The specialty pharmaceutical company earned $1.32 million during the quarter. Does Acura Pharmaceuticals have any subsidiaries? Acura Pharmaceuticals subsidiaries include Acura Pharmaceutical Technologies Inc.. How do I buy shares of Acura Pharmaceuticals? Shares of ACUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Acura Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acura Pharmaceuticals investors own include Denali Therapeutics (DNLI), Ekso Bionics (EKSO), VIVUS (VVUS), Corbus Pharmaceuticals (CRBP), Fulcrum Therapeutics (FULC) and Adamis Pharmaceuticals (ADMP). Company Calendar Last Earnings2/28/2020Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ACUR Previous SymbolNASDAQ:ACUR CUSIP00509L70 CIK786947 Webwww.acurapharm.com Phone(847) 705-7709Fax847-705-5399Employees10Year Founded1935Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$1.56 million Price / Sales0.15 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares66,349,000Free Float52,947,000Market Cap$232,221.50 OptionableNot Optionable Beta1.70 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (OTCMKTS:ACUR) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acura Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acura Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.